Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Outlook For Biogen's Aducanumab Brightens Based On FDA Clues

Nov 04 2020

• By Jessica Merrill

Forest road under sunset beams — Investors have a sunnier outlook for Biogen's aducanumab • Source: Shutterstock

Related Content

Biogen’s Aducanumab: One Positive Phase III Trial Is Good Enough For Demonstrating Efficacy, US FDA Says

Nov 05 2020

USA FDA Gives Biogen Big Hand In Effort To Get Its Alzheimer’s Treatment On The Market

Nov 05 2020

Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

Oct 21 2020

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Mar 22 2019

An About Face As Biogen Says It Will File Aducanumab In Alzheimer’s

Oct 23 2019

Related Companies

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

Advisory Committees Business Strategies Companies Commercial Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window